Tatva Chintan Pharma Chem

Vadodara, India Founded: 1996 • Age: 30 yrs Listed
Pharmaceutical raw materials are manufactured and supplied by the company.
Request Access
Report Incorrect Data
Page last updated

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem is a publicly listed company based in Vadodara (India) founded in 1996 by Chintan Shah, Shekhar Somani, and Ajay Patel. Pharmaceutical raw materials are manufactured and supplied by the company. The company has 939 employees. Its Indian entity Tatva Chintan Pharma Chem Limited reported revenue of ₹509 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Tatva Chintan Pharma Chem was established in 1996 in Vadodara, India, within the pharmaceutical chemicals sector. A range of raw materials, including hydroxides, phase transfer catalysts, quaternary ammonium compounds, quaternary phosphonium compounds, and pyridinium salts, is produced and distributed. Operations are supported by manufacturing facilities certified under ISO 9001:2008 standards, focusing on supply to pharmaceutical applications.

Recognitions & Rankings of Tatva Chintan Pharma Chem

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#487
Valuation
₹5,873 Cr
  • Headquarters Vadodara, India
  • Employees 939
  • Founders Chintan Shah, Shekhar Somani, Ajay Patel
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website tatvachintan.com
  • Social LinkedIn X Facebook
  • Legal Name Tatva Chintan Pharma Chem Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹3,667 Cr

    TATVA · NSE

  • Share Price
    ₹1,605.40

    +2.42% today

  • Revenue
    ₹506 Cr

    FY 2025-26 · +32.2% YoY

  • EBITDA
    ₹93.45 Cr

    Margin 18.5%

  • Net Profit
    ₹42.09 Cr

    FY 2025-26 · +633.3% YoY

  • P/E (TTM)
    57.4x

    P/B 4.5x

  • ROE
    5.5%

    ROCE 7.2%

  • Debt / Equity
    0.10

    Interest cover 5.5x

  • Employee Count
    939

Board of directors of Tatva Chintan Pharma Chem Limited (Tatva Chintan Pharma Chem)

Tatva Chintan Pharma Chem Limited is the primary company behind Tatva Chintan Pharma Chem. The board of Tatva Chintan Pharma Chem Limited currently have 6 directors; the longest-serving is Chintan Nitinkumar Shah, appointed in 1996. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Chintan Nitinkumar Shah
DIN 00183618
Managing Director12 Jun 199630 yrs 4 moTatva Chintan Pharma Chem Limited
Shekhar Rasiklal Somani
DIN 00183665
Whole-time director12 Jun 199630 yrs 4 moTatva Chintan Pharma Chem Limited
Ajaykumar Mansukhlal Patel
DIN 00183745
Whole-time director12 Jun 199630 yrs 4 moTatva Chintan Pharma Chem Limited
Avani Rajesh Umatt
DIN 09046170
Director27 Feb 20215 yrs 7 moTatva Chintan Pharma Chem Limited
Manher Chimanlal Desai
DIN 09042598
Director27 Feb 20215 yrs 7 moTatva Chintan Pharma Chem Limited
Subhash Ambubhai Patel
DIN 00535221
Director27 Feb 20215 yrs 7 moTatva Chintan Pharma Chem Limited

People of Tatva Chintan Pharma Chem

14 people are tracked at Tatva Chintan Pharma Chem (7 in leadership, 7 in team); the tracked headcount is 939.

NameRoleGroup
Chintan Shah
Co-FounderLeadership
Shekhar Somani
Co-FounderLeadership
Ajay Patel
Co-FounderLeadership
Ajay Rawat
Head RndLeadership
Nilesh Parekh
Vice President Human ResourcesLeadership
Chintan Nitinkumar Shah
Chairman & Managing DirectorLeadership
Ritesh Trivedi
Senior General Manager, Global SalesLeadership
Swapnil Padole
Junior ExecutiveTeam
Hemesh Vyas
R D ManagerTeam
Krunal Modi
Human Resources ExecutiveTeam
Pratik Prajapati
Mechanical EngineerTeam
Ishwar Nayi
Company Secretary And Compliance OffierTeam
Dr. Tushar J Trivedi
Assistant Manager(group Leader)Team
Meghshyam Patil
Technology Transfer OfficerTeam
Premium access

Complete people profiles for Tatva Chintan Pharma Chem

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem is a publicly listed company on the NSE with ticker symbol TATVA in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 Jul 2021
  • Listed onBSE: 543321 · NSE: TATVA
  • Listed entityTatva Chintan Pharma Chem Limited
  • Exchange sectorProcess industries
  • ISININE0GK401011
  • Share price₹1,933.10 (+4.99% on the day) · 2026-10-14
  • Market capitalisation₹4,297 Cr
  • Price to earnings88.0
  • EPS (diluted, trailing year)₹21.97
  • Dividend yield0.11%
  • Volume (last session)63,063

Financials of Tatva Chintan Pharma Chem

Exchange-reported figures of Tatva Chintan Pharma Chem Limited, the listed company behind Tatva Chintan Pharma Chem (NSE: TATVA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹506 Cr
+32.2% YoY
EBITDA
₹93.45 Cr
+171.4% YoY
Profit After Tax
₹42.09 Cr
+633.3% YoY
Net Worth
₹782 Cr
+5.8% YoY
Total Assets
₹906 Cr
+16.7% YoY
Total Debt
₹120 Cr
+230.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue506383394424434300263
Revenue growth+32.2%-2.7%-7.1%-2.3%+44.4%+14.1%-
EBITDA93.4534.4368.3957.1910966.6955.28
EBITDA margin+18.5%+9.0%+17.4%+13.5%+25.0%+22.2%+21.0%
Profit before tax57.017.5843.5644.7710460.7147.60
Net profit42.095.7430.4048.7395.9152.3137.82
Net profit margin+8.3%+1.5%+7.7%+11.5%+22.1%+17.4%+14.4%
EPS (₹)17.982.4412.9820.5243.2526.0247.03
Balance sheet
Total assets906777753686594258209
Net worth782739737515473166118
Total debt12036.3914.2717012090.2590.69
Cash & bank8.7914.1038.2944.761775.3410.83
Net working capital25220622224037113097.03
Cash flow
Cash from operations31.4924.7798.0427.7820.3819.6925.31
Cash from investing(116)(65.30)(121)(101)(197)(20.66)(40.18)
Cash from financing78.9316.5930.5237.80235(4.71)9.95
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue21716713413112411710885.90
Revenue growth (YoY)+75.9%+43.0%+24.4%+52.9%+48.0%+10.8%--
Other income1.752.78(0.35)1.731.011.160.720.04
EBITDA40.6930.9828.1225.4822.2217.338.957.06
EBITDA margin+18.7%+18.5%+21.0%+19.4%+18.0%+14.8%+8.3%+8.2%
Depreciation10.7910.579.769.079.058.977.266.92
Interest2.712.081.440.490.510.410.390.42
Profit before tax28.9421.1116.5717.6513.679.112.02(0.24)
Tax7.495.136.262.493.752.451.00(0.38)
Net profit21.4515.9810.3115.169.926.661.020.14
EPS (₹)9.176.834.416.494.242.840.440.06
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue496366379403428291254
Revenue growth+35.5%-3.2%-6.0%-5.8%+46.9%+14.7%-
EBITDA89.4826.0167.0151.2210665.4052.70
EBITDA margin+18.0%+7.1%+17.7%+12.7%+24.8%+22.5%+20.8%
Profit before tax53.160.4742.2638.8310359.3644.22
Net profit39.110.3729.4343.7796.0351.4034.98
Net profit margin+7.9%+0.1%+7.8%+10.9%+22.5%+17.7%+13.8%
EPS (₹)16.710.1412.5518.2643.3125.5743.51
Balance sheet
Total assets882759741676589254206
Net worth758721726505469162114
Total debt12036.3914.2717012090.2590.69
Cash & bank4.5011.9336.9738.581753.599.82
Net working capital22918821022936612593.12
Cash flow
Cash from operations29.1724.0110323.7319.7618.9124.64
Cash from investing(116)(65.38)(121)(101)(197)(20.61)(40.18)
Cash from financing78.9316.5930.5437.82235(4.72)9.70
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue20714713313911610910884.00
Revenue growth (YoY)+79.1%+34.4%+23.2%+65.0%+43.1%+16.4%--
Other income2.714.03(0.37)1.730.791.371.300.04
Total expenses17612410611294.7594.1199.7578.35
EBITDA31.2322.7026.5426.6221.1115.077.905.65
EBITDA margin+15.1%+15.5%+20.0%+19.2%+18.2%+13.8%+7.3%+6.7%
Depreciation10.7910.579.759.079.058.977.266.92
Interest2.712.081.440.490.510.410.390.42
Profit before tax20.4414.0814.9818.7912.347.061.55(1.65)
Tax5.053.655.952.813.401.920.46(0.49)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue21716713413112411710885.90
Revenue growth (YoY)+75.9%+43.0%+24.4%+52.9%+48.0%+10.8%--
Other income1.752.78(0.35)1.731.011.160.720.04
EBITDA40.6930.9828.1225.4822.2217.338.957.06
EBITDA margin+18.7%+18.5%+21.0%+19.4%+18.0%+14.8%+8.3%+8.2%
Depreciation10.7910.579.769.079.058.977.266.92
Interest2.712.081.440.490.510.410.390.42
Profit before tax28.9421.1116.5717.6513.679.112.02(0.24)
Tax7.495.136.262.493.752.451.00(0.38)
Net profit21.4515.9810.3115.169.926.661.020.14
EPS (₹)9.176.834.416.494.242.840.440.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue506383394424434300263
Revenue growth+32.2%-2.7%-7.1%-2.3%+44.4%+14.1%-
Other income3.552.327.515.748.895.201.38
Total expenses412348325366325234208
Employee cost62.9352.9254.7641.2130.8123.8020.53
EBITDA93.4534.4368.3957.1910966.6955.28
EBITDA margin+18.5%+9.0%+17.4%+13.5%+25.0%+22.2%+21.0%
Depreciation36.8527.6625.619.568.186.734.79
Interest3.141.516.738.605.114.454.27
Profit before tax57.017.5843.5644.7710460.7147.60
Tax14.961.8713.22(0.70)8.258.439.81
Net profit42.095.7430.4048.7395.9152.3137.82
Net profit margin+8.3%+1.5%+7.7%+11.5%+22.1%+17.4%+14.4%
EPS (₹)17.982.4412.9820.5243.2526.0247.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.3923.3923.3922.1722.1720.098.04
Reserves & surplus758715714493451146110
Shareholders' funds (net worth)782739737515473166118
Minority interest0.000.000.000.000.000.000.00
Secured loans12036.3914.2717012090.2590.69
Unsecured loans0.000.000.000.000.000.000.00
Total debt12036.3914.2717012090.2590.69
Total liabilities906777753686594258209
Assets
Gross block733617488232186139122
Net block609529427196160120111
Capital work in progress24.9224.3176.5423151.499.814.89
Investments4.000.0010.050.000.000.000.00
Inventories19613415316217072.0263.56
Sundry debtors11989.5569.8584.4056.6090.7449.57
Cash & bank balances8.7914.1038.2944.761775.3410.83
Loans & advances25.6227.6526.9420.5932.3516.158.74
Total current assets350265288312436184133
Total current liabilities97.7759.6366.0372.6764.6154.5335.67
Net working capital25220622224037113097.03
Total assets906777753686594258209
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.3735.3027.3763.024.4810.1615.75
Net cash from operating activities31.4924.7798.0427.7820.3819.6925.31
Net cash from investing activities(116)(65.30)(121)(101)(197)(20.66)(40.18)
Net cash from financing activities78.9316.5930.5237.80235(4.71)9.95
Net change in cash(5.61)(23.93)7.94(35.65)58.54(5.68)(4.92)
Closing cash8.7914.1038.2944.761775.3410.83
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.2%-2.7%-7.1%-2.3%+44.4%+14.1%-
EBITDA growth+171.4%-49.7%+19.6%-47.3%+62.7%+20.6%-
PBT growth+652.1%-82.6%-2.7%-57.0%+71.5%+27.5%+73.8%
Net income growth+633.3%-81.1%-37.6%-49.2%+83.4%+38.3%-
Revenue CAGR (3Y)+6.1%-4.1%+9.4%+17.2%+28.1%+30.3%-
EBITDA CAGR (3Y)+17.8%-31.8%+0.8%+1.1%+47.1%+42.3%-
Profitability & leverage
Net income margin+8.3%+1.5%+7.7%+10.7%+22.1%+17.4%+14.4%
Return on capital employed+7.2%+1.2%+7.0%+8.3%+25.6%+27.9%+28.3%
Return on net worth+5.5%+0.8%+4.9%+9.2%+30.0%+36.9%+38.3%
Debt / equity0.100.030.150.290.330.640.85
Long-term debt / equity0.000.000.000.020.060.230.36
Interest cover5.5522.3015.7318.065.097.428.46
Efficiency & per share
Fixed asset turnover0.750.691.092.032.672.302.69
Inventory turnover3.072.672.502.553.584.435.31
Debtors turnover4.854.805.106.015.894.285.80
EPS (₹)17.982.4412.9820.5243.2526.0247.03
Dividend per share (₹)2.001.002.002.002.005.000.00
Book value per share (₹)334.20315.84315.10232.25213.4482.62146.48
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue20714713313911610910884.00
Revenue growth (YoY)+79.1%+34.4%+23.2%+65.0%+43.1%+16.4%--
Other income2.714.03(0.37)1.730.791.371.300.04
Total expenses17612410611294.7594.1199.7578.35
EBITDA31.2322.7026.5426.6221.1115.077.905.65
EBITDA margin+15.1%+15.5%+20.0%+19.2%+18.2%+13.8%+7.3%+6.7%
Depreciation10.7910.579.759.079.058.977.266.92
Interest2.712.081.440.490.510.410.390.42
Profit before tax20.4414.0814.9818.7912.347.061.55(1.65)
Tax5.053.655.952.813.401.920.46(0.49)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue496366379403428291254
Revenue growth+35.5%-3.2%-6.0%-5.8%+46.9%+14.7%-
Other income3.533.567.515.6810.635.100.56
Total expenses407340312352322226201
Employee cost62.9352.9254.7641.2130.8223.8020.53
EBITDA89.4826.0167.0151.2210665.4052.70
EBITDA margin+18.0%+7.1%+17.7%+12.7%+24.8%+22.5%+20.8%
Depreciation36.8427.6525.609.558.186.734.79
Interest3.011.456.668.525.194.414.25
Profit before tax53.160.4742.2638.8310359.3644.22
Tax14.090.1312.91(1.63)7.287.999.26
Net profit39.110.3729.4343.7796.0351.4034.98
Net profit margin+7.9%+0.1%+7.8%+10.9%+22.5%+17.7%+13.8%
EPS (₹)16.710.1412.5518.2643.3125.5743.51
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.3923.3923.3922.1722.1720.098.04
Reserves & surplus735698702483447142106
Shareholders' funds (net worth)758721726505469162114
Secured loans12036.3914.2717012090.2590.69
Unsecured loans0.000.000.000.000.000.000.00
Total debt12036.3914.2717012090.2590.69
Total liabilities882759741676589254206
Assets
Gross block733617488232186139122
Net block609529427196160120111
Capital work in progress24.9224.3176.5423151.499.814.89
Investments4.670.6710.720.670.670.670.67
Inventories16912314415116168.3658.72
Sundry debtors14490.3367.9590.0461.6090.3450.97
Cash & bank balances4.5011.9336.9738.581753.599.82
Loans & advances24.2725.9634.5227.5456.0916.188.89
Total current assets342252284308453178128
Total current liabilities11363.6973.5878.6786.7353.4435.28
Net working capital22918821022936612593.12
Total assets882759741676589254206
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash9.2133.9921.1960.782.739.1515.67
Net cash from operating activities29.1724.0110323.7319.7618.9124.64
Net cash from investing activities(116)(65.38)(121)(101)(197)(20.61)(40.18)
Net cash from financing activities78.9316.5930.5437.82235(4.72)9.70
Net change in cash(7.74)(24.78)12.80(39.59)58.05(6.42)(5.85)
Closing cash4.5011.9336.9738.581753.599.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+35.5%-3.2%-6.0%-5.8%+46.9%+14.7%-
EBITDA growth+244.0%-61.2%+30.8%-51.7%+62.1%+24.1%-
PBT growth--98.9%+8.8%-62.4%+74.0%+34.2%+67.4%
Net income growth--98.7%-32.8%-54.4%+86.8%+46.9%-
Revenue CAGR (3Y)+7.2%-5.0%+9.2%+16.7%+28.2%+30.5%-
EBITDA CAGR (3Y)+20.4%-37.4%+0.8%-1.0%+47.3%+44.7%-
Profitability & leverage
Net income margin+7.9%+0.1%+7.8%+10.0%+22.4%+17.6%+13.8%
Return on capital employed+6.8%+0.3%+6.9%+7.5%+25.7%+27.7%+26.7%
Return on net worth+5.3%+0.1%+4.8%+8.3%+30.4%+37.2%+36.0%
Debt / equity0.110.040.150.300.330.650.86
Long-term debt / equity0.000.000.000.020.060.240.36
Interest cover5.72-88.4116.0820.455.317.528.87
Efficiency & per share
Fixed asset turnover0.740.661.051.932.632.232.59
Inventory turnover3.392.742.562.583.744.585.65
Debtors turnover4.244.634.795.325.634.125.31
EPS (₹)16.710.1412.5518.2643.3125.5743.51
Dividend per share (₹)2.001.002.002.002.005.000.00
Book value per share (₹)324.14308.36310.31227.74211.5480.61142.44

Similar companies to Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Laurus Labs
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
Symbiotec
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Tatva Chintan Pharma Chem

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Tatva Chintan Pharma Chem

The website of Tatva Chintan Pharma Chem (tatvachintan.com) receives about 2.6K visits a month.

  • Monthly visits
    2.6K

    ▼ 10.6% vs previous month

Similar websites

Websites whose visitors overlap most with Tatva Chintan Pharma Chem. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
HARKE Group
harke.com
100%
#1,841,756View details
jsftchem.com
jsftchem.com
86%
–

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Tatva Chintan Pharma Chem (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tatva Chintan Pharma Chem

TATVA: Q2 REVENUE 2.2B RUPEES VS 1.24B (YOY)
Exchange Update • 9 days ago
TATVA: Q2 CONS NET PROFIT 215M RUPEES VS 99.2M (YOY); EST 139M
Exchange Update • 9 days ago
TATVA: Q2 EBITDA 407M RUPEES VS 222M (YOY); Q2 EBITDA MARGIN 18.71% VS 17.99% (YOY)
Exchange Update • 9 days ago
Tatva Chintan Pharma Chem: Plans Meetings With Various Analysts And Investors On September 23
Exchange Update • 1 month ago
Buy Tatva Chintan Pharma Chem; target of Rs 1955: ICICI Securities
Moneycontrol • 3 months ago
Tatva Chintan Pharma Chem shares surge 16% after Q1 profit doubles; Deven Choksey sees 8% upside
Moneycontrol • 3 months ago
Tatva Chintan Shares Decline 1.89% Ahead of Board Meeting for Quarterly Results
Moneycontrol • 3 months ago
Buy Tatva Chintan Pharma Chem; target of Rs 1955: ICICI Securities
Moneycontrol • 9 months ago
Reduce Tatva Chintan Pharma Chem; target of Rs 1380: Deven Choksey
Moneycontrol • 11 months ago
Tatva Chintan Pharma Chem Sept Quarter Consol Net Profit 99.2 Million Rupees
Reuters • 12 months ago
Premium access

Complete news archive for Tatva Chintan Pharma Chem

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem was founded in 1996.

Tatva Chintan Pharma Chem is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.

Tatva Chintan Pharma Chem has 939 employees.

The primary company behind Tatva Chintan Pharma Chem, Tatva Chintan Pharma Chem Limited, reported revenue of ₹509 Cr for FY 2026, up 32% year on year.

Tatva Chintan Pharma Chem was established in 1996 in Vadodara, India, within the pharmaceutical chemicals sector. A range of raw materials, including hydroxides, phase transfer catalysts, quaternary ammonium compounds, quaternary phosphonium compounds, and pyridinium salts, is produced and distributed. Operations are supported by manufacturing facilities certified under ISO 9001:2008 standards, focusing on supply to pharmaceutical applications.

Tatva Chintan Pharma Chem's top competitors include Laurus Labs, Symbiotec and SeQuent.

Yes, Tatva Chintan Pharma Chem is publicly traded on NSE under the ticker symbol TATVA.

Tatva Chintan Pharma Chem operates through Tatva Chintan Pharma Chem Limited.

The legal entities of Tatva Chintan Pharma Chem currently have 8 directors, including Chintan Nitinkumar Shah, Shekhar Rasiklal Somani, Ajaykumar Mansukhlal Patel and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available